基本信息
浏览量:120
职业迁徙
个人简介
Professor Bountra was previously Vice President and Head of Biology at GlaxoSmithKline. He was involved in the identification of more than 40 clinical candidates for many gastro-intestinal, inflammatory and neuro-psychiatric diseases. More than 20 of these molecules progressed into patient studies and more than five of these delivered successful “Proof of Concept” data and progressed into late stage development. He was involved in the launch and development of the first treatment for Irritable Bowel Syndrome (Alosetron) and was the first to show that neurokinin NK1 antagonists are anti-emetic in preclinical and clinical studies.
His current interests are i) using X ray structures of novel human proteins to generate small molecule inhibitors, screening in human cells to identify novel targets for drug discovery, and then developing clinical candidates for evaluation in patients, pre-competitively ii) focussing on epigenetic and genetically identified proteins, because these are likely to represent better targets for drug discovery, for many cancer, inflammatory, metabolic and neuro-psychiatric diseases iii) working with colleagues in Oxford to build major programmes in rare diseases and in Alzheimers Disease, and creating a “BioEscalator” for the rapid translation of science and iv) building stronger links with local hospitals, patient groups, regulatory agencies, private investors, CROs, biotechs and large pharma companies, to create a new, more efficient ecosystem for pioneer drug discovery.
He is an invited expert on several government and charitable research funding bodies, and an advisor for many academic, biotech and pharma drug discovery programmes.
His current interests are i) using X ray structures of novel human proteins to generate small molecule inhibitors, screening in human cells to identify novel targets for drug discovery, and then developing clinical candidates for evaluation in patients, pre-competitively ii) focussing on epigenetic and genetically identified proteins, because these are likely to represent better targets for drug discovery, for many cancer, inflammatory, metabolic and neuro-psychiatric diseases iii) working with colleagues in Oxford to build major programmes in rare diseases and in Alzheimers Disease, and creating a “BioEscalator” for the rapid translation of science and iv) building stronger links with local hospitals, patient groups, regulatory agencies, private investors, CROs, biotechs and large pharma companies, to create a new, more efficient ecosystem for pioneer drug discovery.
He is an invited expert on several government and charitable research funding bodies, and an advisor for many academic, biotech and pharma drug discovery programmes.
研究兴趣
论文共 216 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Sarah Picaud,Oleg Fedorov,Angeliki Thanasopoulou, Katharina Leonards, Katherine Jones, Julia Meier,Heidi Olzscha,Octovia Monteiro,Sarah Martin,Martin Philpott,Anthony Tumber,Panagis Filippakopoulos,
crossref(2023)
Sarah Picaud,Oleg Fedorov,Angeliki Thanasopoulou, Katharina Leonards, Katherine Jones,Julia Meier,Heidi Olzscha,Octovia Monteiro,Sarah Martin,Martin Philpott,Anthony Tumber,Panagis Filippakopoulos,
crossref(2023)
crossref(2023)
Guisong Wang,Punit Shah, Richard Searfoss,Jianfang Liu, Jamie Leigh Campbell,Brenda Deyarmin,Rebecca Zingmark,Bradley Mostoller,Leonid Kvecher,Stella Somiari,Praveen-Kumar Raj-Kumar,Lori Sturtz,
Research Square (Research Square) (2022)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn